PDF(Pubmed)
Abstract：
OBJECTIVE: To identify the current practices with long half-life lipoglycopeptides (LGPs) and potential use/position of oritavancin.
RESULTS: Despite their indication being limited to skin and soft tissue infections (SSTIs), long half-life lipoglycopeptides are mainly used off-label to treat bone and joint infections (BJIs) and infective endocarditis. Oritavancin and dalbavancin are both semisynthetic lipoglycopeptide antibiotics with activity against Gram-positive organisms. The game-changing property of these two antibiotics is their one-time dosing. Due to its shorter half-life, oritavancin might have an advantage over dalbavancin for a treatment duration of less than 2 weeks, as it could be used both in prolonged treatments of complicated patients in BJIs or administered as a single-dose treatment for Gram-positive cocci infections usually treated by a 5- to 10-day antibiotic course. These infections include urinary tract infections, bacteremias, catheter-related infections, etc. In addition to the possibility of being used as an end-of-treatment injection, oritavancin could be used as an empiric therapy treatment in the postoperative period in the context of device-associated especially prosthetic joint infections to allow for the early discharge of the patient.
METHODS: A qualitative survey was conducted in March 2022 including sixteen infectiologists, one internist, five hospital pharmacists, and one pharmacologist.
CONCLUSIONS: Long half-life lipoglycopeptides contribute to changing the paradigm in the management of acute bacterial infections, as infectiologists now consider a range of indications and patient profiles for one single drug. Oritavancin strengthens the therapeutic arsenal in numerous infections from BJIs to urinary tract infections and could help to manage specific clinical situations, on top of providing potential benefits for the hospital\'s budget.
RESULTS: Despite their indication being limited to skin and soft tissue infections (SSTIs), long half-life lipoglycopeptides are mainly used off-label to treat bone and joint infections (BJIs) and infective endocarditis. Oritavancin and dalbavancin are both semisynthetic lipoglycopeptide antibiotics with activity against Gram-positive organisms. The game-changing property of these two antibiotics is their one-time dosing. Due to its shorter half-life, oritavancin might have an advantage over dalbavancin for a treatment duration of less than 2 weeks, as it could be used both in prolonged treatments of complicated patients in BJIs or administered as a single-dose treatment for Gram-positive cocci infections usually treated by a 5- to 10-day antibiotic course. These infections include urinary tract infections, bacteremias, catheter-related infections, etc. In addition to the possibility of being used as an end-of-treatment injection, oritavancin could be used as an empiric therapy treatment in the postoperative period in the context of device-associated especially prosthetic joint infections to allow for the early discharge of the patient.
METHODS: A qualitative survey was conducted in March 2022 including sixteen infectiologists, one internist, five hospital pharmacists, and one pharmacologist.
CONCLUSIONS: Long half-life lipoglycopeptides contribute to changing the paradigm in the management of acute bacterial infections, as infectiologists now consider a range of indications and patient profiles for one single drug. Oritavancin strengthens the therapeutic arsenal in numerous infections from BJIs to urinary tract infections and could help to manage specific clinical situations, on top of providing potential benefits for the hospital\'s budget.
摘要：
目的：确定当前具有长半衰期脂糖肽（LGP）的实践以及奥利万星的潜在用途/位置。
结果：尽管其适应症仅限于皮肤和软组织感染（STTI），长半衰期脂糖肽主要用于治疗骨和关节感染（BJIs）和感染性心内膜炎。Oritavancin和dalbavancin都是半合成脂糖肽抗生素，具有抗革兰氏阳性生物的活性。这两种抗生素的改变游戏规则的特性是它们的一次性给药。由于其半衰期较短，oritavancin可能比dalbavancin有优势，治疗时间少于2周，因为它既可以用于BJIs复杂患者的长期治疗，也可以作为革兰氏阳性球菌感染的单剂量治疗，通常通过5至10天的抗生素疗程治疗。这些感染包括尿路感染，菌血症,导管相关感染,等。除了可能用作治疗结束注射外，oritavancin可用作术后期间的经验性治疗,尤其是与装置相关的人工关节感染,以便患者早期出院.
方法：2022年3月进行了一项定性调查，包括16名感染学家，一个内科医生,五名医院药剂师,还有一位药理学家.
结论：长半衰期的脂糖肽有助于改变急性细菌感染的管理模式，因为感染学家现在考虑一种单一药物的一系列适应症和患者概况。Oritavancin加强了从BJI到尿路感染的众多感染的治疗武器库，并有助于管理特定的临床情况，除了为医院的预算提供潜在的好处。
结果：尽管其适应症仅限于皮肤和软组织感染（STTI），长半衰期脂糖肽主要用于治疗骨和关节感染（BJIs）和感染性心内膜炎。Oritavancin和dalbavancin都是半合成脂糖肽抗生素，具有抗革兰氏阳性生物的活性。这两种抗生素的改变游戏规则的特性是它们的一次性给药。由于其半衰期较短，oritavancin可能比dalbavancin有优势，治疗时间少于2周，因为它既可以用于BJIs复杂患者的长期治疗，也可以作为革兰氏阳性球菌感染的单剂量治疗，通常通过5至10天的抗生素疗程治疗。这些感染包括尿路感染，菌血症,导管相关感染,等。除了可能用作治疗结束注射外，oritavancin可用作术后期间的经验性治疗,尤其是与装置相关的人工关节感染,以便患者早期出院.
方法：2022年3月进行了一项定性调查，包括16名感染学家，一个内科医生,五名医院药剂师,还有一位药理学家.
结论：长半衰期的脂糖肽有助于改变急性细菌感染的管理模式，因为感染学家现在考虑一种单一药物的一系列适应症和患者概况。Oritavancin加强了从BJI到尿路感染的众多感染的治疗武器库，并有助于管理特定的临床情况，除了为医院的预算提供潜在的好处。
